Product
Brigimadlin
Aliases
Brigimadlin (BI 907828)
Name
Brigimadlin
2 clinical trials
2 indications
Indication
LiposarcomaIndication
DedifferentiatedClinical trial
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated LiposarcomaStatus: Active (not recruiting), Estimated PCD: 2024-04-16
Clinical trial
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated LiposarcomaStatus: Recruiting, Estimated PCD: 2025-11-24